Anyone can_老虎社区_美港股上老虎

Jfamily
2021-11-29

Anyone can say anything at this point. Pick who you like to believe.

The Omicron Variant May Be a Buying Opportunity, but Only for the Brave

The sharp selloff that hit global markets Friday is easing, with stocks clawing back ground early Mo

The Omicron Variant May Be a Buying Opportunity, but Only for the Brave

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":600764529,"tweetId":"600764529","gmtCreate":1638198848026,"gmtModify":1638198848401,"author":{"id":3581650998573030,"idStr":"3581650998573030","authorId":3581650998573030,"authorIdStr":"3581650998573030","name":"Jfamily","avatar":"https://static.tigerbbs.com/a3aebdda0a7db817f943bd9c7990f11b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":14,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Anyone can say anything at this point. Pick who you like to believe.&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Anyone can say anything at this point. Pick who you like to believe.&nbsp;</p></body></html>","text":"Anyone can say anything at this point. Pick who you like to believe.","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/600764529","repostId":1131565631,"repostType":4,"repost":{"id":"1131565631","pubTimestamp":1638189275,"share":"https://www.laohu8.com/m/news/1131565631?lang=&edition=full","pubTime":"2021-11-29 20:34","market":"us","language":"en","title":"The Omicron Variant May Be a Buying Opportunity, but Only for the Brave","url":"https://stock-news.laohu8.com/highlight/detail?id=1131565631","media":"Barrons","summary":"The sharp selloff that hit global markets Friday is easing, with stocks clawing back ground early Mo","content":"<p>The sharp selloff that hit global markets Friday is easing, with stocks clawing back ground early Monday.</p>\n<p>It’s too early to class Friday’s slump an overreaction but it may well have been a knee-jerk one, given the lack of information available about the new Omicron variant of the coronavirus that causes Covid-19.</p>\n<p>We still don’t know enough to decide if this is a buying opportunity—one bad headline could well reignite the selloff. Yet a couple of developments appear to have eased fears for now. The World Health Organization cautioned against travel restrictions, recommending countries take a “risk-based and scientific approach.” The WHO also said there was no information to suggest the symptoms linked to the variant are any different from other strains. Health experts in South Africa have also described symptoms as mild.</p>\n<p>Even in the event of a worst-case scenario—the variant proves to be vaccine-busting—&nbsp;Moderna&nbsp;said it could have a modified vaccine ready in early 2022.</p>\n<p>That development, in particular, serves as a reminder that the world is in a far better place to cope with the pandemic than it was in March 2020.</p>\n<p>Hedge fund manager Bill Ackman said if the Omicron variant does indeed prove to cause mild to moderate symptoms, even if it is more transmissible, that would be bullish for stocks.</p>\n<p>He may well be right but for now that is a big ‘if,’ and one that is unlikely to be fully answered for at least a couple of volatile and uncertain weeks.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Omicron Variant May Be a Buying Opportunity, but Only for the Brave</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Omicron Variant May Be a Buying Opportunity, but Only for the Brave\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 20:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/things-to-know-today-51638180720?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The sharp selloff that hit global markets Friday is easing, with stocks clawing back ground early Monday.\nIt’s too early to class Friday’s slump an overreaction but it may well have been a knee-jerk ...</p>\n\n<a href=\"https://www.barrons.com/articles/things-to-know-today-51638180720?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.barrons.com/articles/things-to-know-today-51638180720?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131565631","content_text":"The sharp selloff that hit global markets Friday is easing, with stocks clawing back ground early Monday.\nIt’s too early to class Friday’s slump an overreaction but it may well have been a knee-jerk one, given the lack of information available about the new Omicron variant of the coronavirus that causes Covid-19.\nWe still don’t know enough to decide if this is a buying opportunity—one bad headline could well reignite the selloff. Yet a couple of developments appear to have eased fears for now. The World Health Organization cautioned against travel restrictions, recommending countries take a “risk-based and scientific approach.” The WHO also said there was no information to suggest the symptoms linked to the variant are any different from other strains. Health experts in South Africa have also described symptoms as mild.\nEven in the event of a worst-case scenario—the variant proves to be vaccine-busting— Moderna said it could have a modified vaccine ready in early 2022.\nThat development, in particular, serves as a reminder that the world is in a far better place to cope with the pandemic than it was in March 2020.\nHedge fund manager Bill Ackman said if the Omicron variant does indeed prove to cause mild to moderate symptoms, even if it is more transmissible, that would be bullish for stocks.\nHe may well be right but for now that is a big ‘if,’ and one that is unlikely to be fully answered for at least a couple of volatile and uncertain weeks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1095,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":56,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

The Omicron Variant May Be a Buying Opportunity, but Only for the Brave

评论（2）

热议股票